RxDoctor Payments Data

Emily O'Dell, DO

Family Medicine · Derby, KSNPI 1083095970

Payments from drug & device makers

$242in general payments, 2019–2025

Across 15 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$70
  • Amgen$63
  • Boehringer Ingelheim$35
  • Boston Scientific$14
  • GSK$13
  • Johnson & Johnson$12
  • plus $34 from 3 others

What the payments were for

  • Food & beverage$22994%
  • Education$146%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$242 in reported general payments places this provider in the 35th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$98,543
Medicare patients
265
Services billed
1,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$90,712
JardianceEmpagliflozin93$89,731
TrulicityDulaglutide34$46,355
EliquisApixaban59$35,607
JanuviaSitagliptin Phosphate36$29,777
FarxigaDapagliflozin Propanediol25$22,403
Xultophy 100-3.6Insulin Degludec/Liraglutide18$21,600
MounjaroTirzepatide20$20,541
XareltoRivaroxaban16$18,561
LinzessLinaclotide29$17,479
VraylarCariprazine Hcl12$17,077
Tresiba Flextouch U-100Insulin Degludec24$11,274
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$11,145
TradjentaLinagliptin11$6,702
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$4,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6$70$112,311107 claims
Boehringer IngelheimJardiance, Tradjenta$35$96,434104 claims
MerckJanuvia$11$29,77736 claims
Johnson & JohnsonXarelto$12$18,56116 claims
GSKTrelegy Ellipta, Anoro Ellipta$13$15,76431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Derby

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →